You are here:
NICE
NICE Guidance
Published Guidance
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Technology appraisal guidance
Reference number:
TA472
Published:
30 August 2017
This guidance has been updated and replaced by
NICE technology appraisal guidance 629
.